Wave Life Sciences, Inc. (WVE) shareholders
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (16.80%), Peter Kolchinsky (16.80%) and 1 more | 34,314,406 | 16.80% | 13D (active) amendment | Aug 7, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (17.10%), Rajeev Shah (17.10%) and 1 more | 34,225,506 | 17.10% | 13D (active) amendment | Apr 15, 2026 |
| BlackRock, Inc. | 13,356,138 | 6.80% | 13G (passive) | Sep 30, 2026 |
| Maverick Capital, Ltd. Joint filing with Maverick Capital Management, LLC (5.40%), Lee S. Ainslie III (5.40%) | 8,261,242 | 5.40% | 13G (passive) amendment | Dec 31, 2024 |
| Phillip Gross Joint filing with Adage Capital Partners, L.P. (5.03%), Adage Capital Partners GP, L.L.C. (5.03%) and 2 more | 5,987,730 | 5.03% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of WVE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 26,975,505 | 13.68% | $156.73M | – | 1.36% |
| BlackRock, Inc. | 19,202,461 | 9.74% | $111.57M | +5,085,049 | 0.00% |
| GSK plc | 18,245,691 | 9.25% | $106.01M | – | 17.60% |
| Maverick Capital Ltd | 10,278,115 | 5.21% | $59.72M | +116,716 | 0.53% |
| Driehaus Capital Management LLC | 5,443,143 | 2.76% | $31.62M | +12,122 | 0.18% |
| Primecap Management Co/Ca/ | 5,354,622 | 2.71% | $31.11M | +521,670 | 0.02% |
| 683 Capital Management, LLC | 4,950,000 | 2.51% | $28.76M | +50,000 | 1.41% |
| FMR LLC | 4,922,477 | 2.50% | $28.60M | −270,284 | 0.00% |
| State Street Corp | 4,839,317 | 2.45% | $28.12M | +1,165,284 | 0.00% |
| Readystate Asset Management LP | 4,727,139 | 2.40% | $27.46M | New | 0.94% |
| M28 Capital Management LP | 4,588,284 | 2.33% | $26.66M | – | 56.53% |
| Geode Capital Management, LLC | 3,869,998 | 1.96% | $22.49M | +290,899 | 0.00% |
| Two Sigma Investments, LP | 3,707,686 | 1.88% | $21.54M | +1,829,571 | 0.02% |
| Algert Global LLC | 2,817,615 | 1.43% | $16.37M | +1,502,026 | 0.19% |
| Qube Research & Technologies Ltd | 2,776,000 | 1.41% | $16.13M | +2,620,076 | 0.01% |
| Squarepoint Ops LLC | 2,541,442 | 1.29% | $14.77M | +1,079,052 | 0.02% |
| Morgan Stanley | 2,422,705 | 1.23% | $14.08M | +1,061,704 | 0.00% |
| Vanguard Portfolio Management LLC | 2,110,751 | 1.07% | $12.26M | +934,544 | 0.00% |
| Pfizer Inc | 1,875,000 | 0.95% | $10.93M | – | 6.42% |
| Millennium Management LLC | 1,811,282 | 0.92% | $10.52M | +839,041 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 239 | 183M | 92.6% | 50 / 100 | 54 / 37 | 38M | 27M |
| Q1 2026 | 232 | 173M | 87.5% | 51 / 107 | 48 / 35 | 37M | 44M |
| Q4 2025 | 219 | 183M | 92.7% | 73 / 78 | 48 / 38 | 64M | 25M |
| Q3 2025 | 189 | 145M | 73.3% | 32 / 62 | 61 / 18 | 16M | 11M |
| Q2 2025 | 176 | 139M | 70.5% | 23 / 84 | 39 / 40 | 14M | 6M |
| Q1 2025 | 196 | 131M | 66.7% | 34 / 83 | 52 / 20 | 10M | 7M |
| Q4 2024 | 183 | 129M | 65.3% | 46 / 75 | 39 / 24 | 19M | 11M |
| Q3 2024 | 162 | 121M | 61.2% | 37 / 60 | 38 / 17 | 42M | 10M |
| Q2 2024 | 144 | 96M | 48.5% | 36 / 48 | 45 / 23 | 10M | 10M |
| Q1 2024 | 132 | 95M | 48.2% | 34 / 54 | 32 / 16 | 12M | 10M |
| Q4 2023 | 115 | 93M | 47.3% | 40 / 48 | 11 / 10 | 21M | 1M |
| Q3 2023 | 85 | 73M | 36.8% | 11 / 28 | 28 / 7 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
63 funds held WVE in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of WVE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1,751,923 | 0.89% | $10.18M | 0.01% | Jun 30, 2026 |
| Driehaus Small Cap Growth Fund | 741,885 | 0.38% | $4.31M | 0.27% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 718,284 | 0.36% | $4.73M | 0.03% | May 31, 2026 |
| North Square Dynamic Small Cap Fund | 707,270 | 0.36% | $4.65M | 0.59% | May 31, 2026 |
| Vanguard Strategic Equity Fund | 424,855 | 0.22% | $2.47M | 0.02% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF | 394,231 | 0.20% | $2.29M | 0.20% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 387,093 | 0.20% | $2.25M | 0.02% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 386,104 | 0.20% | $2.13M | 0.01% | Jul 31, 2026 |
| Small Cap Equity Fund | 340,145 | 0.17% | $1.98M | 0.19% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 334,797 | 0.17% | $2.20M | 0.01% | May 31, 2026 |
| Emerald Growth Fund | 308,183 | 0.16% | $2.18M | 0.15% | Apr 30, 2026 |
| SmallCap Growth Fund I | 305,452 | 0.15% | $1.68M | 0.07% | Jul 31, 2026 |
| Driehaus Micro Cap Growth Fund | 234,606 | 0.12% | $1.36M | 0.23% | Jun 30, 2026 |
| Vanguard Explorer Fund | 211,153 | 0.11% | $1.16M | 0.01% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 195,202 | 0.10% | $1.08M | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Bolno | President and CEO, Director | 275,520 | 0.14% | Feb 11, 2026 |
| Erik Ingelsson | Chief Scientific Officer | 87,864 | 0.04% | Apr 17, 2026 |
| Christopher I. Wright | Chief Medical Officer | 45,625 | 0.02% | Apr 17, 2026 |
| Chris Francis | See Remarks | 61,867 | 0.03% | Feb 27, 2026 |
| Chandra Vargeese | See Remarks | 408,246 | 0.21% | Feb 11, 2026 |
| Kyle Moran | Chief Financial Officer | 134,385 | 0.07% | Feb 11, 2026 |
| Heidi L. Wagner | Director | 55,630 | 0.03% | Oct 7, 2026 |
| Aik Na Tan | Director | 35,668 | 0.02% | Oct 7, 2026 |
| Adrian Rawcliffe | Director | 10,700 | 0.01% | Oct 7, 2026 |
| Gregory L. Verdine | Director | 275,917 | 0.14% | Oct 7, 2026 |
| Mark Corrigan | Director | 39,515 | 0.02% | Oct 7, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 28,815 | 0.01% | Oct 7, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Oct 7, 2026 |
| Peter Kolchinsky | Director, 10% owner | 19,202,009 | 9.74% | Oct 7, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 39,515 | 0.02% | Oct 7, 2026 |
| Christian O. Henry | Director | 23,400 | 0.01% | Oct 7, 2026 |
| Ken Takanashi | Director | 9,637,187 | 4.89% | Oct 7, 2026 |
| plc GSK | 10% owner | 18,245,691 | 9.25% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. Director, 10% owner | Oct 5, 2026 | Award | +10,700 | – | – | 39,515 |
| Gregory L. Verdine Director | Oct 5, 2026 | Award | +10,700 | – | – | 200,917 |
| Aik Na Tan Director | Oct 5, 2026 | Award | +10,700 | – | – | 35,668 |
| Ken Takanashi Director | Oct 5, 2026 | Award | +10,700 | – | – | 30,779 |
| Mark Corrigan Director | Oct 5, 2026 | Award | +10,700 | – | – | 39,515 |
| Adrian Rawcliffe Director | Oct 5, 2026 | Award | +10,700 | – | – | 10,700 |
| Christian O. Henry Director | Oct 5, 2026 | Award | +10,700 | – | – | 23,400 |
| Heidi L. Wagner Director | Oct 5, 2026 | Award | +10,700 | – | – | 55,630 |
| Adrian Rawcliffe Director | Aug 12, 2026 | Sale(10b5-1 plan) | −12,700 | $5.29 | $67.18K | 0 |
| Aik Na Tan Director | Aug 11, 2026 | Sale(10b5-1 plan) | −432 | $6.01 | $2.60K | 24,968 |
| Heidi L. Wagner Director | Aug 11, 2026 | Option exercise | +7,000 | $5.97 | $41.79K | 51,930 |
| Heidi L. Wagner Director | Aug 11, 2026 | Sale(10b5-1 plan) | −7,000 | $6.01 | $42.07K | 44,930 |
| Ken Takanashi Director | Aug 11, 2026 | Sale(10b5-1 plan) | −3,864 | $6.01 | $23.22K | 20,079 |
| Ra Capital Management, L.P. Director, 10% owner | Mar 30, 2026 | Buy | +971,091 | $6.50 | $6.31M | 26,975,505 |
| Ra Capital Management, L.P. Director, 10% owner | Mar 27, 2026 | Buy | +2,495,623 | $6.43 | $16.05M | 26,004,414 |
| Ra Capital Management, L.P. Director, 10% owner | Mar 26, 2026 | Buy | +4,954,558 | $6.06 | $30.02M | 23,157,567 |
| Ra Capital Management, L.P. Director, 10% owner | Mar 26, 2026 | Buy | +351,224 | $6.38 | $2.24M | 23,508,791 |
| Ken Takanashi Director | Mar 23, 2026 | Conversion | +3,901,348 | – | – | 9,606,408 |
| Chris Francis See Remarks | Feb 26, 2026 | Sale(10b5-1 plan) | −15,294 | $15.00 | $229.41K | 61,867 |
| Chris Francis See Remarks | Feb 26, 2026 | Option exercise | +15,294 | $4.75 | $72.65K | 77,161 |
| Chris Francis See Remarks | Feb 26, 2026 | Sale(10b5-1 plan) | −17,900 | $15.09 | $270.11K | 61,867 |
| Chris Francis See Remarks | Feb 26, 2026 | Option exercise | +17,900 | $3.87 | $69.27K | 79,767 |
| Paul Bolno President and CEO, Director | Feb 9, 2026 | Sale | −10,480 | $13.45 | $140.96K | 275,520 |
| Kyle Moran Chief Financial Officer | Feb 9, 2026 | Sale | −3,588 | $13.45 | $48.26K | 134,385 |
| Chandra Vargeese See Remarks | Feb 9, 2026 | Sale | −3,228 | $13.45 | $43.42K | 408,246 |
| Chris Francis See Remarks | Feb 9, 2026 | Sale | −1,883 | $13.45 | $25.33K | 61,867 |
| Paul Bolno President and CEO, Director | Feb 5, 2026 | Award | +165,000 | – | – | 286,000 |
| Kyle Moran Chief Financial Officer | Feb 5, 2026 | Award | +45,625 | – | – | 137,973 |
| Chandra Vargeese See Remarks | Feb 5, 2026 | Award | +45,625 | – | – | 411,474 |
| Chris Francis See Remarks | Feb 5, 2026 | Award | +38,750 | – | – | 63,750 |
| Chris Francis See Remarks | Jan 2, 2026 | Sale(10b5-1 plan) | −8,080 | $15.92 | $128.63K | 26,295 |
| Chris Francis See Remarks | Jan 2, 2026 | Option exercise | +9,375 | $3.14 | $29.44K | 34,375 |
| Chris Francis See Remarks | Jan 2, 2026 | Sale(10b5-1 plan) | −1,295 | $16.70 | $21.63K | 25,000 |
| plc GSK 10% owner | Dec 11, 2025 | Buy | +1,470,000 | $19.00 | $27.93M | 18,245,691 |
| Kyle Moran Chief Financial Officer | Dec 9, 2025 | Option exercise | +36,000 | $8.17 | $294.12K | 125,218 |
| Kyle Moran Chief Financial Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −36 | $20.25 | $729 | 89,218 |
| Kyle Moran Chief Financial Officer | Dec 9, 2025 | Option exercise | +50,000 | $10.48 | $524.00K | 139,218 |
| Kyle Moran Chief Financial Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −50,000 | $20.03 | $1.00M | 90,365 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −50,000 | $18.00 | $900.00K | 89,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Option exercise | +100,000 | $3.14 | $314.00K | 189,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −50,000 | $15.00 | $750.00K | 139,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −50,000 | $13.20 | $660.00K | 89,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Option exercise | +50,000 | $4.75 | $237.50K | 139,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −60,000 | $13.20 | $792.00K | 89,218 |
| Kyle Moran Chief Financial Officer | Dec 8, 2025 | Option exercise | +60,000 | $2.83 | $169.80K | 149,218 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +22,500 | $2.83 | $63.68K | 47,500 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −50,000 | $16.00 | $800.00K | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +50,000 | $10.48 | $524.00K | 75,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −122,349 | $14.20 | $1.74M | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +122,349 | $4.75 | $581.16K | 147,349 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −17,900 | $15.00 | $268.50K | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +17,900 | $3.87 | $69.27K | 42,900 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −37,500 | $14.08 | $528.00K | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +37,500 | $3.14 | $117.75K | 62,500 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −9,375 | $15.00 | $140.63K | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +9,375 | $3.14 | $29.44K | 34,375 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −45,882 | $14.50 | $665.29K | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +45,882 | $4.75 | $217.94K | 70,882 |
| Chris Francis See Remarks | Dec 8, 2025 | Sale(10b5-1 plan) | −107,400 | $14.56 | $1.56M | 25,000 |
| Chris Francis See Remarks | Dec 8, 2025 | Option exercise | +107,400 | $3.87 | $415.64K | 132,400 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Wave Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 62,579 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Adrian Rawcliffe Director | Aug 12, 2026 | 12,700 | $64.07K | Aug 12, 2026 | Restricted Stock Units |
| Heidi L. Wagner Director | Aug 11, 2026 | 7,000 | $42.49K | Aug 11, 2026 | Exercise of Stock Options |
| Kyle Moran Officer | Feb 9, 2026 | 3,564 | $47.94K | Feb 9, 2026 | Restricted Stock Unit Vesting |
| Chris Francis Officer | Feb 9, 2026 | 1,870 | $25.15K | Feb 9, 2026 | Restricted Stock Unit Vesting |
| Paul Bolno Officer | Feb 9, 2026 | 10,411 | $140.03K | Feb 9, 2026 | Restricted Stock Unit Vesting |
| Kyle Moran Officer | Dec 9, 2025 | 86,000 | $1.59M | Dec 9, 2025 | Exercise of Stock Options |
| Henry Family Trust Affiliate | Dec 8, 2025 | 93,445 | $1.73M | Dec 8, 2025 | Transfer, acquired via Stock Option Exercise |
| Heidi L. Wagner Director | Dec 8, 2025 | 14,000 | $104.86K | Dec 8, 2025 | Exercise of Stock Options |
| Kyle Moran Officer | Dec 8, 2025 | 210,000 | $1.57M | Dec 8, 2025 | Exercise of Stock Options |
| Christopher Francis Officer | Dec 8, 2025 | 483,602 | $3.62M | Dec 8, 2025 | Exercise of Stock Options |
| Gregory L. Verdine Director | Dec 8, 2025 | 20,000 | $149.80K | Dec 8, 2025 | Previously Exercised Stock Options |
| Adrian Rawcliffe Director | Dec 8, 2025 | 42,000 | $314.58K | Dec 8, 2025 | Exercise of Stock Options |
| Aik Na Tan Director | Dec 8, 2025 | 134,218 | $1.82M | Dec 8, 2025 | Stock Option Exercise |
| Mark Corrigan Director | Dec 8, 2025 | 16,115 | $120.70K | Dec 8, 2025 | Restricted Stock Units |
| Adrian Rawcliffe Director | Nov 13, 2025 | 16,115 | $112.08K | Nov 13, 2025 | Restricted Stock Units |
See a number that looks wrong?